지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.108 No.3
- 발행연도
- 2025.3
- 수록면
- 186 - 197 (12page)
이용수
초록· 키워드
오류제보하기
Purpose: Regenerative medicine is expected to offer an alternative to liver transplantation for treating liver diseases in the future, with one significant challenge being the establishment of an effective stem cell administration route. This study assessed the antifibrogenic effects of adipose-derived stem cells (ASCs) in a liver fibrosis mouse model, focusing on 2 methods of delivery: intravenous injection and scaffold implantation.
Methods: An extracellular matrix mimic scaffold was utilized for culturing peroxisome proliferator-activated receptor gamma coactivator 1-alpha–overexpressing ASCs (tASCs). These scaffolds, laden with tASCs, were then implanted subcutaneously in mice exhibiting liver fibrosis. In contrast, the Cell groups received biweekly intravenous injections of tASCs for 4 weeks. After 4 weeks, tissue samples were harvested from the euthanized mice for subsequent analysis.
Results: Real-time PCR and Western blot analyses on liver tissues, focusing on markers like alpha-smooth muscle actin (α-SMA), matrix metalloproteinase-2, and transforming growth factor-beta 1 (TGF-β1), showed that both delivery routes substantially lowered fibrotic and inflammatory markers compared to controls (P < 0.05), with no significant differences between the routes. Histological examinations, along with immunohistochemical analysis of α-SMA, collagen type I alpha, and TGF-β1, revealed that the scaffold implantation approach resulted in a greater reduction in fibrosis and lower immunoreactivity for fibrotic markers than intravenous delivery (P < 0.05).
Conclusion: These findings indicate that delivering tASCs via a scaffold could be more effective, or at least similarly effective, in treating liver fibrosis compared to intravenous delivery. Scaffold implantation could offer a beneficial alternative to frequent intravenous treatments, suggesting its potential utility in clinical applications for liver disease treatment.
Methods: An extracellular matrix mimic scaffold was utilized for culturing peroxisome proliferator-activated receptor gamma coactivator 1-alpha–overexpressing ASCs (tASCs). These scaffolds, laden with tASCs, were then implanted subcutaneously in mice exhibiting liver fibrosis. In contrast, the Cell groups received biweekly intravenous injections of tASCs for 4 weeks. After 4 weeks, tissue samples were harvested from the euthanized mice for subsequent analysis.
Results: Real-time PCR and Western blot analyses on liver tissues, focusing on markers like alpha-smooth muscle actin (α-SMA), matrix metalloproteinase-2, and transforming growth factor-beta 1 (TGF-β1), showed that both delivery routes substantially lowered fibrotic and inflammatory markers compared to controls (P < 0.05), with no significant differences between the routes. Histological examinations, along with immunohistochemical analysis of α-SMA, collagen type I alpha, and TGF-β1, revealed that the scaffold implantation approach resulted in a greater reduction in fibrosis and lower immunoreactivity for fibrotic markers than intravenous delivery (P < 0.05).
Conclusion: These findings indicate that delivering tASCs via a scaffold could be more effective, or at least similarly effective, in treating liver fibrosis compared to intravenous delivery. Scaffold implantation could offer a beneficial alternative to frequent intravenous treatments, suggesting its potential utility in clinical applications for liver disease treatment.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Toward angiogenesis of implanted bio-artificial liver using scaffolds with type I collagen and adipose tissue-derived stem cells
Annals of Hepato-Biliary-Pancreatic Surgery
2015 .05
-
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Clinical and Molecular Hepatology
2021 .01
-
비침습적 간섬유화 검사의 적용
대한내과학회지
2023 .04
-
Liver
대한외과학회 학술대회 초록집
2016 .11
-
Mineral deposition and vascular invasion of hydroxyapatite reinforced collagen scaffolds seeded with human adipose-derived stem cells
생체재료학회지
2019 .01
-
Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
Clinical and Molecular Hepatology
2021 .01
-
Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
Diabetes and Metabolism Journal
2022 .07
-
Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
Diabetes and Metabolism Journal
2023 .01
-
Scaffolds for Tissue Engineering
대한치과재료학회 학술대회
2019 .04
-
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Clinical and Molecular Hepatology
2023 .02
-
Current role of transient elastography in the management of chronic hepatitis B patients
ULTRASONOGRAPHY
2017 .01
-
A novel autophagy inducer, AS777, ameliorates liver fibrosis via suppressing liver inflammation
한국실험동물학회 학술발표대회 논문집
2019 .01
-
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Clinical and Molecular Hepatology
2023 .01
-
Muscle Quality as a Potential Diagnostic Marker of Advanced Liver Fibrosis in Patients with Non-alcoholic Fatty Liver Disease
Journal of Obesity & Metabolic Syndrome
2024 .06
-
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2022 .07
-
Increased Expression of TGF-β1 in Correlation with Liver Fibrosis during Echinococcus granulosus Infection in Mice
Parasites, Hosts and Diseases
2016 .08
-
Magnetization-tagged MRI is a simple method for predicting liver fibrosis
Clinical and Molecular Hepatology
2016 .01
-
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .04
-
Clinical application of liver stiffness measurement for assessing the risk of hepatocellular Carcinoma
Journal of Liver Cancer
2019 .01
-
Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source
Clinical and Molecular Hepatology
2020 .01
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-151-25-02-092528187